慢性乙型肝炎常见PC/BCP突变的可能致病机制

摘要/Abstract

摘要： 乙型肝炎病毒(HBV)感染是慢性肝炎、肝硬化及原发性肝癌的主要病因。慢性感染过程中,导致乙型肝炎e抗原(HBeAg)表达下降/消失的HBV突变株逐渐转换为优势株,其中以基本核心启动子区(BCP)和前核心区(PC)突变最为常见,突变病毒累积造成具有不良预后的HBeAg阴性患者占比逐年上升。近几年的研究表明,突变病毒不仅促进HBV复制,还能诱导病毒蛋白在肝细胞内堆积,堆积的病毒蛋白将诱发肝细胞内质网应激致肝细胞病变。本文对突变诱导的肝细胞病变机制进行探讨,旨在为及时调整治疗策略提供依据。

关键词: 乙型肝炎病毒, 慢性乙型肝炎, PC/BCP突变, 致病机制

李明慧, 王麟, 鲁凤民. 慢性乙型肝炎常见PC/BCP突变的可能致病机制[J]. 肝脏, 2024, 29(4): 371-373.

/ 推荐

参考文献

[1] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2023,30:1309-1331.
[2] Lau DTY, Ganova-Raeva L, Wang J, et al. Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes[J]. Hepatology,2021,73:1637-1651.
[3] Buckwold VE, Xu Z, Chen M, et al. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication[J]. J Virol, 1996,70:5845-5851.
[4] Lee WM, King WC, Janssen HLA, et al. Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study[J]. J Viral Hepat, 2021,28:1526-1538.
[5] Chen MT, Billaud JN, Sällberg M, et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen[J]. Proc Natl Acad Sci U S A, 2004,101:14913-14918.
[6] Luo Y, Zhang L, Dai Y, et al. Conservative Evolution of Hepatitis B Virus Precore and Core Gene During Immune Tolerant Phase in Intrafamilial Transmissio[J]n. Virol Sin, 2020,35:388-397.
[7] Frelin L, Wahlström T, Tucker AE, et al. A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection[J]. J Virol, 2009,83:1379-1392.
[8] Yang D, Zou J, Wang L, et al. Letter to the editor: HBeAg expression suppressing/abolishing mutation elevated HBV DNA level in HBeAg-negative patients with chronic HBV infection[J]. Hepatology,2022,76:E69-E70.
[9] Wu JF, Chang KC, Ni YH, et al. Impacts of the Percentage of Basal Core Promoter Mutation on the Progression of Liver Fibrosis After Hepatitis B e Antigen Seroconversion[J]. J Infect Dis, 2021,223:1381-1389.
[10] Tseng TC, Liu CJ, Yang HC, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers[J]. Gut,2015,64:292-302.
[11] Chachá SGF, Gomes-Gouvêa MS, Malta FM, et al. Basal core promoter and precore mutations among hepatitis B virus circulating in Brazil and its association with severe forms of hepatic diseases[J]. Mem Inst Oswaldo Cruz, 2017,112:626-631.
[12] Wei F, Zheng Q, Li M, et al. The association between hepatitis B mutants and hepatocellular carcinoma: A meta-analysis[J]. Medicine (Baltimore),2017,96:e6835.
[13] Zheng J, Jiang S, Lu F. Possible Involvement of Multidrug-Resistant Hepatitis B Virus sW172* Truncation Variant in the ER Stress Signaling Pathway during Hepatocarcinogenesis[J]. Jpn J Infect Dis, 2016,69:306-313.
[14] Uchida T, Imamura M, Hayes CN, et al. HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice[J]. Hepatology,2023,78:929-942.
[15] Li G, Yang D, Liu X, et al. Precore mutation enhances viral replication to facilitate persistent infection especially in HBeAg-negative patients[J]. Virol Sin, 2024.
[16] Jilg N, Baumert TF. Unfolding the mechanism of hepatocyte injury of HBV precore and core promoter variants[J]. Hepatology,2023,78:702-705.
[17] Yang D, Zou J, Guan G, et al. The A1762T/G1764A mutations enhance HBV replication by alternating viral transcriptome[J]. J Med Virol,2023,95:e29129.
[18] Liu Y, Zhao ZH, Lv XQ, et al. Precise analysis of the effect of basal core promoter/precore mutations on the main phenotype of chronic hepatitis B in mouse models[J]. J Med Virol, 2020,92:3412-3419.
[19] Kazim SN, Chauhan R, Das BC, et al. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy[J]. J Gastroenterol Hepatol, 2006,21:1525-1532.
[20] Chen CH, Lee CM, Lu SN, et al. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy[J]. J Hepatol,2006,44:76-82.
[21] Bayliss J, Yuen L, Rosenberg G, et al. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B[J]. Gut,2017,66:2013-2023.
[22] Yang HC, Chen CL, Shen YC, et al. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion[J]. Hepatology,2013,57:934-943.